eXoZymes, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EXOZ Nasdaq 2836 www.exozymes.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for eXoZymes, Inc.

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - May 7th, 2026 7:05 am
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - Apr 10th, 2026 7:10 am
MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ... - Apr 6th, 2026 7:00 pm
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Mar 31st, 2026 9:02 pm
eXoZymes Q4 Earnings Call Highlights - Mar 31st, 2026 5:07 pm
eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Mar 31st, 2026 2:20 pm
MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter - Mar 31st, 2026 2:05 pm
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - Mar 25th, 2026 2:10 pm
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - Mar 18th, 2026 7:10 am
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium - Mar 12th, 2026 2:15 pm
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation - Feb 10th, 2026 2:20 pm
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run - Jan 29th, 2026 5:45 pm
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion - Dec 11th, 2025 2:10 pm
EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ... - Nov 13th, 2025 10:07 pm
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today - Nov 13th, 2025 2:30 pm
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff - Nov 13th, 2025 2:15 pm
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST - Nov 10th, 2025 3:00 pm
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference - Oct 30th, 2025 2:10 pm
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference - Oct 29th, 2025 3:40 pm
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference - Oct 23rd, 2025 2:50 pm